After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

C4.4A / LYPD3 Antibody (PE), Rabbit MAb

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Human LYPD3 Antibody Product Information
Immunogen:Recombinant Human C4.4A / LYPD3 protein (Catalog#11836-H08H)
Clone ID:213
Ig Type:Rabbit IgG
Concentration:10 μl/Test, 0.1 mg/ml
Formulation:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Human C4.4A / LYPD3 (rh C4.4A / LYPD3; Catalog#11836-H08H; NP_055215.2; Met1-His286) and conjugated with PE under optimum conditions, the unreacted PE was removed.
Human LYPD3 Antibody Usage Guide
Specificity:Human C4.4A / LYPD3
Storage:This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Human LYPD3 Antibody FC Application Image
[Click to enlarge image]
Flow cytometric analysis of Human LYPD3 expression on PC-3 cells.
C4.4A / LYPD3 Antibody (PE), Rabbit MAb, Flow cytometric analysis
Other LYPD3 Antibody Products
C4.4A/LYPD3 Background

Ly6 / PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4 and LYPD3, is a cell membrane protein which contains two UPAR/Ly6 domains. Human LYPD3 contains two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression

Human C4.4A/LYPD3 References
  • Smith B.A., et al., 2001, Cancer Res. 61:1678-85.
  • Wuerfel J., et al., 2001, Gene 262:35-41.
  • Clark H.F., et al., 2003, Genome Res. 13:2265-70.
  • Fletcher G.C., et al., 2003, Br. J. Cancer 88:579-85.
  • Hansen L.V., et al., 2004, Biochem. Eng. J. 380:845-57.
  • Product nameProduct name